{"product_id":"igc-vrio-analysis","title":"India Globalization Capital, Inc. (IGC): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to India Globalization Capital, Inc. (IGC)'s market position as we dissect its core capabilities through the rigorous VRIO lens. This analysis distills whether its current assets truly deliver sustainable competitive advantage by examining their Value, Rarity, Inimitability, and Organization. Dive in now to see the definitive verdict on what makes India Globalization Capital, Inc. (IGC) uniquely powerful - or potentially vulnerable - in today's landscape.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIndia Globalization Capital, Inc. (IGC) - VRIO Analysis: 1. Proprietary AI Drug Discovery Platform (MINT-AD)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at India Globalization Capital, Inc. (IGC) and trying to figure out if their technology bets, like the MINT-AD platform, are real competitive moats or just expensive science projects. Honestly, for a company with only $1.11 million in trailing twelve-month revenue for fiscal year 2025, the value proposition of MINT-AD is entirely tied to future drug success, not current sales. That’s the biotech reality check we need to start with.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Accelerating Discovery and Pipeline Depth\u003c\/h3\u003e\n\u003cp\u003eThe MINT-AD platform, which stands for Multimodal Interpretable Transformer for Alzheimer's, clearly adds value by accelerating candidate identification and optimization. This is directly visible in the advancement of IGC-AD1, their lead asset, which is in Phase 2 trials for Alzheimer's agitation. The platform’s ability to screen proprietary molecules faster is crucial when the company posted a net loss of approximately $7.121 million in FY 2025; speed saves cash. It’s a tool designed to reduce the time and cost to get assets like IGC-AD1 to later clinical stages.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Unique Data Integration\u003c\/h3\u003e\n\u003cp\u003eWhile many firms use AI, IGC’s specific application within MINT-AD for cannabinoid\/small-molecule screening in Central Nervous System (CNS) disorders is moderately rare. The platform’s rarity comes from the sheer breadth of its training data. IGC Pharma is leveraging data from 14 large-scale longitudinal aging and cognition studies spanning the USA, Africa, Mexico, China, and several other countries, all adhering to the Health and Retirement Study (HRS) protocol. That global, diverse dataset is not something every small-cap biotech has access to.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Proprietary Algorithms and Data Moat\u003c\/h3\u003e\n\u003cp\u003eImitating MINT-AD is difficult because its core value is locked in the proprietary algorithms and, more importantly, the unique, curated data sets it has been trained on over time. You can buy similar computing power, but you can’t easily replicate years of specialized data ingestion and refinement. This is further supported by the fact that IGC Pharma secured a USPTO Patent covering IGC-AD1 in November 2025, which protects a key output of their R\u0026amp;D process.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Active Commercialization and Pipeline Support\u003c\/h3\u003e\n\u003cp\u003eThe organization is demonstrably leveraging this asset, which is key to realizing any value. We see this in the operational momentum: the CALMA trial for IGC-AD1 passed the 50% patient enrollment milestone by November 17, 2025, and reached 65% enrollment by December 9, 2025. This progress absorbed a significant portion of the $3.655 million in Research \u0026amp; Development expenses reported for Fiscal Year 2025. The planned launch of a beta version of MINT-AD in Fiscal 2026 also shows management is organizing around its commercial potential.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Assessment\u003c\/h3\u003e\n\u003cp\u003eRight now, the competitive advantage is best classified as Temporary. AI platforms evolve incredibly fast; what’s leading-edge today might be standard in 18 months. However, the current integration - linking MINT-AD's predictive power to the clinical advancement of IGC-AD1 - provides a short-term lead in discovery speed and patient stratification for their trials.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment for MINT-AD:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eScore (1-4)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes, accelerates drug pipeline (IGC-AD1)\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eModerately Rare (Unique global data integration)\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult (Proprietary algorithms and trained data)\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eHigh (Active use in achieving trial milestones)\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003e14\/16\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the risk that IGC-AD1 fails its Phase 2 trial, which would render the MINT-AD advantage purely diagnostic rather than therapeutic-enabling. Still, the platform is clearly a strategic asset.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY 2025 Net Loss improved by 45% year-over-year to approx. $7.121 million.\u003c\/li\u003e\n\u003cli\u003eTTM Revenue for FY 2025 was only $1.11 million USD.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spending in FY 2025 totaled $3.655 million.\u003c\/li\u003e\n\u003cli\u003eCALMA trial enrollment reached 65% as of December 9, 2025.\u003c\/li\u003e\n\u003cli\u003eMINT-AD training utilizes data from 14 longitudinal studies globally.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIndia Globalization Capital, Inc. (IGC) - VRIO Analysis: 2. Lead Clinical Asset (IGC-AD1) in Advanced Trial Stage\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Represents the highest potential near-term payoff, targeting agitation in Alzheimer's disease (AD) with dual-action potential against amyloid and tau.\u003c\/p\u003e\n\u003cp\u003eIGC-AD1 demonstrated potential in preclinical models, showing a reduction in amyloid plaque aggregation by approximately \u003cstrong\u003e20%\u003c\/strong\u003e and improved spatial memory by about \u003cstrong\u003e50%\u003c\/strong\u003e in mouse models. The Phase 2 CALMA trial interim data showed a statistically significant reduction in sleep disturbances, with a reduction of about \u003cstrong\u003e71%\u003c\/strong\u003e at week 2 (p=.012) and about \u003cstrong\u003e78%\u003c\/strong\u003e at week 6 (p=.02) on the NPI-12 Sleep Subscale. Exploratory data indicated an average improvement of about \u003cstrong\u003e8%\u003c\/strong\u003e on the Mini-Mental State Examination ('MMSE') over six weeks in the active treatment group, versus no improvement in placebo. Agitation reduction was observed as early as \u003cstrong\u003etwo weeks\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many AD candidates exist, but IGC-AD1 is in a late-stage Phase 2 trial (CALMA), which is a significant hurdle cleared.\u003c\/p\u003e\n\u003cp\u003eThe Phase 2 CALMA trial has reached \u003cstrong\u003e65%\u003c\/strong\u003e patient enrollment as of December 9, 2025, out of a planned enrollment of \u003cstrong\u003e146\u003c\/strong\u003e participants. The company aims for trial completion in \u003cstrong\u003eearly 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific compound and its trial data are proprietary, though competitors can develop similar mechanisms.\u003c\/p\u003e\n\u003cp\u003eIGC has secured \u003cstrong\u003e28\u003c\/strong\u003e patent filings related to its assets. The drug is described as a proprietary cannabinoid-based partial CB1 receptor agonist.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management is intensely focused on completing the trial, which reached \u003cstrong\u003e65%\u003c\/strong\u003e enrollment by December 2025.\u003c\/p\u003e\n\u003cp\u003eThe company's market capitalization as of November 2025 was approximately \u003cstrong\u003e$33.83 million USD\u003c\/strong\u003e. The Research \u0026amp; Development (R\u0026amp;D) cost totaled \u003cstrong\u003e$3.655 million\u003c\/strong\u003e in Fiscal Year 2025. The company's trailing twelve-month revenue for FY 2025 was reported as \u003cstrong\u003e$1.11 million USD\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe following table summarizes key interim clinical data points for IGC-AD1:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eResult\/Value\u003c\/td\u003e\n\u003ctd\u003eTime Point\/Context\u003c\/td\u003e\n\u003ctd\u003eCitation Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep Disturbance Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e71%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWeek 2 vs. Placebo (NPI-12)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep Disturbance Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e78%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWeek 6 vs. Placebo (NPI-12)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMMSE Improvement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e8%\u003c\/strong\u003e average improvement\u003c\/td\u003e\n\u003ctd\u003eActive Group over 6 weeks (Exploratory)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgitation Reduction\u003c\/td\u003e\n\u003ctd\u003eSignificant reduction\u003c\/td\u003e\n\u003ctd\u003eObserved as early as \u003cstrong\u003e2 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmyloid Plaque Reduction (Preclinical)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e20%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAlzheimer's cell lines\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe focus on recruitment efficiency and market potential is supported by the following statistics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAgitation is a symptom affecting over \u003cstrong\u003e76%\u003c\/strong\u003e of individuals living with Alzheimer's disease.\u003c\/li\u003e\n\u003cli\u003eThe CALMA trial is designed to enroll \u003cstrong\u003e146\u003c\/strong\u003e participants.\u003c\/li\u003e\n\u003cli\u003eThe recruitment strategy utilized digital outreach, with \u003cstrong\u003e25%\u003c\/strong\u003e of enrolled participants coming through social-media campaigns and \u003cstrong\u003e75%\u003c\/strong\u003e through clinical-site efforts.\u003c\/li\u003e\n\u003cli\u003eA pilot recruitment campaign achieved a \u003cstrong\u003e200-300%\u003c\/strong\u003e increase in enrollment at a relatively \u003cstrong\u003elow cost per lead\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe global market for Alzheimer's agitation therapies was valued at over \u003cstrong\u003e$2.8bn in 2024\u003c\/strong\u003e, projected to exceed \u003cstrong\u003e$4.9bn\u003c\/strong\u003e by the end of the decade.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (if successful); successful Phase 2\/3 data creates a strong moat around the specific therapeutic approach.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIndia Globalization Capital, Inc. (IGC) - VRIO Analysis: 3. Patent Protection for Key Drug Candidate (IGC-AD1)\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue: Provides a legal monopoly over the IGC-AD1 composition, protecting future revenue streams from direct generic competition for a set period.\u003c\/h\u003e\n\u003cp\u003eThe patent protection grants a legal barrier against direct generic competition for the IGC-AD1 composition, which utilizes a low-dose THC-based formulation for Alzheimer's agitation.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity: Rare; patent grants are a significant, hard-won barrier to entry in the pharma space.\u003c\/h\u003e\n\u003cp\u003eIGC holds over 30 patent filings and 12 granted patents as of November 2025.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability: Very Low; competitors cannot legally copy the patented composition.\u003c\/h\u003e\n\u003cp\u003eLegal exclusivity prevents direct replication of the patented composition. The drug candidate, IGC-AD1, is the only natural, THC-based investigational drug candidate currently undergoing FDA trials on Alzheimer's.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization: High; the patent was granted in November 2025, showing active IP management aligned with clinical progress.\u003c\/h\u003e\n\u003cp\u003eThe organization demonstrates active IP management, evidenced by the 12 granted patents and the progression of IGC-AD1 into a Phase 2 clinical trial for agitation in Alzheimer's dementia.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIGC-AD1 is currently in a 146-person Phase 2 safety and efficacy clinical trial (NCT05543681).\u003c\/li\u003e\n\u003cli\u003ePhase I completion resulted in a Phase Transition Success Rate (PTSR) of 73%.\u003c\/li\u003e\n\u003cli\u003ePhase I completion resulted in a Likelihood of Approval (LoA) of 9%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained; this is the definition of a legal, sustained advantage in drug development.\u003c\/h\u003e\n\u003cp\u003eThe legal protection afforded by the patent is the foundation for a sustained advantage, contingent upon successful trial progression. As of November 2025, the company's market capitalization was approximately $33.83 million USD.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Date Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33.83 million USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing Twelve Month (TTM) Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.11 million USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.121 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIGC-AD1 Clinical Phase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePhase 2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase I PTSR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost Phase I Completion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eIndia Globalization Capital, Inc. (IGC) - VRIO Analysis: 4. Cost-Efficient Clinical Trial Execution Model\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Extends capital runway by significantly lowering operational burn rate; clinical trial costs are maintained at \u003cstrong\u003e\\$50,000-\\$75,000\u003c\/strong\u003e per patient, below the industry standard of \u003cstrong\u003e\\$100,000-\\$150,000\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eIGC Model Cost (Per Patient)\u003c\/th\u003e\n\u003cth\u003eIndustry Standard Cost (Per Patient)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost Range\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$50,000 - \\$75,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$100,000 - \\$150,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expense (FY2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$3.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expense (FY2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; this specific, documented cost advantage in patient recruitment and management is not common for small-cap biotechs.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eClinical trial expenses in India are approximately \u003cstrong\u003e50%\u003c\/strong\u003e lower than in the U.S. and Europe.\u003c\/li\u003e\n\u003cli\u003eIGC-AD1 Phase 2 trial expansion across North America sites to accelerate enrollment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; it requires a specific internal team structure and disciplined vendor management to replicate.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSelling, General, and Administrative (“SG\u0026amp;A”) expenses decreased by \u003cstrong\u003e28%\u003c\/strong\u003e (\u003cstrong\u003e\\$462,000\u003c\/strong\u003e) to \u003cstrong\u003e\\$1.2 million\u003c\/strong\u003e in Q1 FY2026 through headcount alignment and improved vendor management.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this focus on cost-efficiency is a stated strategic priority to minimize dilution.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Loss for Fiscal Year 2025 was approximately \u003cstrong\u003e\\$7.121 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRaised \u003cstrong\u003e\\$3.5 million\u003c\/strong\u003e via private placements and ATM offering in Q1 FY2026.\u003c\/li\u003e\n\u003cli\u003eExtended an undrawn \u003cstrong\u003e\\$12 million\u003c\/strong\u003e credit facility with O-Bank.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; while effective now, other firms could adopt similar lean operational strategies.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIndia Globalization Capital, Inc. (IGC) - VRIO Analysis: 5. Diversified Early-Stage Drug Pipeline\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e IGC-AD1 is in \u003cstrong\u003ePhase II\u003c\/strong\u003e clinical trial for agitation in dementia due to Alzheimer's. The pipeline provides optionality beyond IGC-AD1, including TGR-63, which demonstrated ability to cross the blood-brain barrier with a favorable safety profile on July 9, 2024. IGC-1C, a small-molecule modulator targeting tau protein phase separation, showed promising preclinical results on August 22, 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The portfolio addresses multiple Alzheimer's pathways, including amyloid-beta plaques (IGC-AD1), tau pathology (IGC-1C), and potential neuroinflammation\/metabolic targets (IGC-1C, IGC-1A). Preclinical analyses for TGR-63 demonstrated crossing the blood-brain barrier.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Preclinical data and specific molecular structures are proprietary.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Research and Development (R\u0026amp;D) expenses for the quarter ended September 30, 2024 (Q2 FY2025) were approximately \u003cstrong\u003e$917 thousand\u003c\/strong\u003e. The company secured \u003cstrong\u003eUS$1 million\u003c\/strong\u003e from Bradbury Investment Fund in September.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Preclinical assets can be quickly surpassed by better-funded competitors.\u003c\/p\u003e\n\u003cp\u003eThe diversification across the pipeline is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDrug Candidate\u003c\/th\u003e\n\u003cth\u003eTarget Pathway\/Mechanism\u003c\/th\u003e\n\u003cth\u003eStage\/Key Finding\u003c\/th\u003e\n\u003cth\u003eRelevant Metric\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIGC-AD1\u003c\/td\u003e\n\u003ctd\u003eAmyloid-beta plaques and Tau pathology (Dual-Action)\u003c\/td\u003e\n\u003ctd\u003ePhase II clinical trial\u003c\/td\u003e\n\u003ctd\u003eTreatment of agitation in dementia due to Alzheimer's\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTGR-63\u003c\/td\u003e\n\u003ctd\u003eAlzheimer's Disease\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eDemonstrated ability to cross the blood-brain barrier (July 9, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIGC-1C\u003c\/td\u003e\n\u003ctd\u003eTau protein phase separation\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003ePromising results announced (August 22, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIGC-1A\u003c\/td\u003e\n\u003ctd\u003eMetabolic Disorders\/GLP-1 Agonist\u003c\/td\u003e\n\u003ctd\u003ePreclinical (AI Identified)\u003c\/td\u003e\n\u003ctd\u003eIdentified as potential GLP-1 agonist (August 20, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePreclinical trials of IGC-AD1 showed mice treated exhibited a \u003cstrong\u003e50 percent improvement\u003c\/strong\u003e in learning errors compared with the control group in the Morris water maze task.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIGC Pharma reported Revenue of approximately \u003cstrong\u003e$412 thousand\u003c\/strong\u003e in Q2 FY2025, a \u003cstrong\u003e42%\u003c\/strong\u003e increase over Q2 FY 2024.\u003c\/li\u003e\n\u003cli\u003eSelling, General \u0026amp; Administrative (SG\u0026amp;A) expenses decreased by \u003cstrong\u003e25%\u003c\/strong\u003e to approximately \u003cstrong\u003e$1 million\u003c\/strong\u003e in Q2 FY2025 compared to Q2 FY 2024.\u003c\/li\u003e\n\u003cli\u003eThe net loss for Q2 FY2025 decreased to approximately \u003cstrong\u003e$1.7 million\u003c\/strong\u003e or \u003cstrong\u003e$0.02\u003c\/strong\u003e per share, compared to approximately \u003cstrong\u003e$2.5 million\u003c\/strong\u003e or \u003cstrong\u003e$0.05\u003c\/strong\u003e per share for Q2 FY 2024.\u003c\/li\u003e\n\u003cli\u003eFor Fiscal Year 2025 (ended March 31, 2025), the Net Loss was approximately \u003cstrong\u003e$7.121 million\u003c\/strong\u003e, a \u003cstrong\u003e45%\u003c\/strong\u003e improvement compared to the \u003cstrong\u003e$13 million\u003c\/strong\u003e loss in FY 2024.\u003c\/li\u003e\n\u003cli\u003eGross profit for FY 2025 was \u003cstrong\u003e$619 thousand\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIndia Globalization Capital, Inc. (IGC) - VRIO Analysis: 6. Modest, Revenue-Generating Life Sciences Commercial Arm\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Generates a small but consistent revenue stream from wellness products and white-label services to help offset operational costs. The revenue for the Life Sciences segment was reported as $1,271 thousand for Fiscal Year 2025, an increase from $1,181 thousand in Fiscal 2024. The segment generated a Gross Profit of $619 thousand for FY 2025.\u003c\/p\u003e\n\u003cp\u003eThe financial contribution of this segment relative to the total company performance is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY 2025 Amount\u003c\/th\u003e\n\u003cth\u003eFY 2024 Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLife Sciences Segment Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,271 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,181 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Company Revenue (TTM)\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$1.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$1.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment Gross Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$619 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many clinical-stage firms lack any commercial revenue stream.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy; competitors could launch similar wellness\/white-label products, though IGC has existing B2B relationships. The commercial activities include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSale of formulations as white-labeled manufactured products.\u003c\/li\u003e\n\u003cli\u003eScientifically formulated, non-CBD-based wellness products for immunity and energy.\u003c\/li\u003e\n\u003cli\u003eWholesale of hemp extracts, including hemp crude extract and hemp isolate.\u003c\/li\u003e\n\u003cli\u003eTolling services, such as extraction and distillation, to hemp farmers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; this segment is maintained but clearly secondary to the drug pipeline development. The Company reported Selling, General and Administrative (SG\u0026amp;A) expenses for Fiscal 2025 at approximately $4.4 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; this is a supporting activity, not a source of sustained advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIndia Globalization Capital, Inc. (IGC) - VRIO Analysis: 7. Strategic Capital Structure Management\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Ensures operational continuity and reduces shareholder dilution by securing necessary funding through non-dilutive means when possible, such as the \u003cstrong\u003e$12 million\u003c\/strong\u003e revolving line of credit secured in July 2023. This funding is primarily designated to support working capital needs related to Alzheimer's research.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; securing credit is standard, but the specific terms of the \u003cstrong\u003e$12 million\u003c\/strong\u003e facility from O-Bank, which included a \u003cstrong\u003e$120,000\u003c\/strong\u003e fee for the initial 12-month duration and a draw limit of up to \u003cstrong\u003e$1 million\u003c\/strong\u003e within a 30-day period, are specific to the company's current stage and banking relationship.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific terms of the renewed credit facility and the strategic capital allocation following the divestiture of the Infrastructure segment are unique to IGC's current operational focus on Life Sciences. The company has strategically divested its low-margin Infrastructure segment to concentrate capital on the high-potential Life Sciences segment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company actively uses asset sales (divestiture of the Infrastructure segment) and credit lines to fund operations, showing clear financial planning to support its clinical pipeline, evidenced by the focus on the Phase 2 IGC-AD1 trial.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; credit lines must be renewed, and asset sales are finite resources. The company's current financial health profile reflects a clinical-stage biotechnology company, reporting a Net Loss of approximately \u003cstrong\u003e$7.121 million\u003c\/strong\u003e for Fiscal Year 2025.\u003c\/p\u003e\n\n\u003cp\u003eThe capital structure management is best illustrated by the recent financial activities and structure:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\/Event\u003c\/th\u003e\n\u003cth\u003eAmount\/Detail\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevolving Line of Credit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSecured July 2023 for Alzheimer's research working capital.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLine of Credit Fee\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$120,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFee paid to O-Bank for the 12-month facility.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum Draw Period\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1 million\u003c\/strong\u003e within a \u003cstrong\u003e30-day\u003c\/strong\u003e period\u003c\/td\u003e\n\u003ctd\u003eTerm of the $12 million credit facility.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$7.121 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFY ending March 31, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 Gross Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$619 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDerived almost entirely from the Life Sciences segment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets (Mar 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet figure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities (Mar 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet figure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe company's reliance on non-dilutive financing is a key element of its current strategy, especially following the pivot:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe strategic shift involved divesting the Infrastructure segment, which generated revenue in the three months ended June 30, 2019, but had \u003cstrong\u003enil\u003c\/strong\u003e revenue in Fiscal Year 2025.\u003c\/li\u003e\n\u003cli\u003eThe company secured an investment of \u003cstrong\u003e$3 million\u003c\/strong\u003e led by Bradbury Asset Management funds prior to the line of credit.\u003c\/li\u003e\n\u003cli\u003eThe company is listed on NYSE American with approximately \u003cstrong\u003e92.87 million\u003c\/strong\u003e shares outstanding as of late 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIndia Globalization Capital, Inc. (IGC) - VRIO Analysis: 8. Legacy Infrastructure Business Knowledge Base\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a historical foundation in international operations, logistics, and commodity trading, which could be leveraged for future non-pharma ventures or supply chain insights, though revenue was nil in FY2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; few clinical-stage biotechs have deep, established infrastructure\/commodity trading roots in India.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; replicating the established operational footprint and relationships in India would take years.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low; the CEO reviews performance on an entity level, suggesting the infrastructure segment is not an active resource allocation focus. The company's strategic pivot is evidenced by the allocation of resources toward its Life Sciences pipeline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this advantage is decaying as the company focuses on pharma, definitely.\u003c\/p\u003e\n\u003cp\u003eThe strategic shift away from the legacy business is quantified by the following financial and operational data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLegacy Infrastructure Segment (Context\/FY2025)\u003c\/th\u003e\n\u003cth\u003eLife Sciences Segment (FY2025 Focus)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (FY2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$1.271 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue (FY2025)\u003c\/td\u003e\n\u003ctd\u003ePart of the business with nil revenue\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$1.271 million\u003c\/strong\u003e, nearly all total revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development (R\u0026amp;D) Investment (FY2025)\u003c\/td\u003e\n\u003ctd\u003eNot the primary recipient\u003c\/td\u003e\n\u003ctd\u003eBulk of the \u003cstrong\u003e$3.7 million\u003c\/strong\u003e in R\u0026amp;D expenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManagement Commentary on Transition\u003c\/td\u003e\n\u003ctd\u003eManagement initiated efforts to rightsize legacy segments as early as Q3 2016\u003c\/td\u003e\n\u003ctd\u003ePrimary operational focus as of November 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe historical knowledge base represents an asset that is currently underutilized or de-emphasized in the current corporate strategy, as reflected in the following operational details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue for the former Infrastructure segment was reported as \u003cstrong\u003e$0\u003c\/strong\u003e in Fiscal Year 2025.\u003c\/li\u003e\n\u003cli\u003eTotal company revenue for Fiscal Year 2025 was approximately \u003cstrong\u003e$1.271 million\u003c\/strong\u003e, derived almost entirely from the Life Sciences segment.\u003c\/li\u003e\n\u003cli\u003eThe company reported a Net Loss of approximately \u003cstrong\u003e$7.121 million\u003c\/strong\u003e for FY 2025.\u003c\/li\u003e\n\u003cli\u003eSelling, General and Administrative (SG\u0026amp;A) expenses were reduced by approximately \u003cstrong\u003e$2.3 million\u003c\/strong\u003e, or \u003cstrong\u003e35%\u003c\/strong\u003e, to about \u003cstrong\u003e$4.4 million\u003c\/strong\u003e in FY 2025 compared to the prior year, reflecting cost control across the board.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIndia Globalization Capital, Inc. (IGC) - VRIO Analysis: 9. Insider Confidence and Analyst Support\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInsider purchases over the last year: \u003cstrong\u003e$13.7M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eHigh-impact open-market insider purchases: \u003cstrong\u003e$400.0K\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAscendiant Capital latest price target: \u003cstrong\u003e$4.75\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePositive insider buying is rare; analyst coverage is common for listed firms.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInsider conviction is based on private knowledge; analyst reports are based on public perception.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManagement communication of milestones, such as the \u003cstrong\u003e65%\u003c\/strong\u003e patient enrollment milestone in the Phase 2 CALMA trial.\u003c\/li\u003e\n\u003cli\u003eFiscal Year \u003cstrong\u003e2025\u003c\/strong\u003e Research \u0026amp; Development expenses: approximately \u003cstrong\u003e$3.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTemporary; this is sentiment-driven and can reverse quickly on negative trial news.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eStatistical and Financial Data Summary:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Insider Purchases (Last Year)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.7M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOver the last year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAscendiant Capital Price Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.75\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest reported target.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 CALMA Trial Enrollment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e65%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePatient enrollment milestone achieved.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 R\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e92.87 M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent count.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (Approx.)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.67 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of recent reports.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyst Median Target (4 Analysts)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.88\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMedian forecast from 4 analysts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eAnalyst Coverage Details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNumber of analysts providing price forecasts: \u003cstrong\u003e4\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnalyst consensus rating: \u003cstrong\u003eModerate Buy\u003c\/strong\u003e (based on 2 Buy, 1 Hold rating).\u003c\/li\u003e\n\u003cli\u003eAnalyst consensus rating (Alternative source): \u003cstrong\u003eStrong Buy\u003c\/strong\u003e (based on 2 analysts).\u003c\/li\u003e\n\u003cli\u003eAnalyst Price Target Range: Low: \u003cstrong\u003e$3.25\u003c\/strong\u003e, High: \u003cstrong\u003e$4.50\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnalyst Price Target Range (Alternative source): Low: \u003cstrong\u003e$3.00\u003c\/strong\u003e, High: \u003cstrong\u003e$4.50\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eZacks Research Downgrade: From “strong-buy” to “hold” on November 12th.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516185436309,"sku":"igc-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/igc-vrio-analysis.png?v=1740184276","url":"https:\/\/dcf-model.com\/fr\/products\/igc-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}